These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37516125)

  • 1. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Pozo-Rosich P; Ailani J; Ashina M; Goadsby PJ; Lipton RB; Reuter U; Guo H; Schwefel B; Lu K; Boinpally R; Miceli R; De Abreu Ferreira R; McCusker E; Yu SY; Severt L; Finnegan M; Trugman JM
    Lancet; 2023 Sep; 402(10404):775-785. PubMed ID: 37516125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
    Tassorelli C; Nagy K; Pozo-Rosich P; Lanteri-Minet M; Sacco S; Nežádal T; Guo H; De Abreu Ferreira R; Forero G; Trugman JM
    Lancet Neurol; 2024 Apr; 23(4):382-392. PubMed ID: 38364831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.
    Goadsby PJ; Friedman DI; Holle-Lee D; Demarquay G; Ashina S; Sakai F; Neel B; Gandhi P; Dabruzzo B; Smith JH; Liu Y; Trugman JM
    Neurology; 2024 Jul; 103(2):e209584. PubMed ID: 38924724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
    Lipton RB; Pozo-Rosich P; Blumenfeld AM; Dodick DW; McAllister P; Li Y; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    JAMA Netw Open; 2022 Jun; 5(6):e2215499. PubMed ID: 35675076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atogepant for the Preventive Treatment of Migraine.
    Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM;
    N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
    Ashina M; Tepper SJ; Reuter U; Blumenfeld AM; Hutchinson S; Xia J; Miceli R; Severt L; Finnegan M; Trugman JM
    Headache; 2023 Jan; 63(1):79-88. PubMed ID: 36651532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
    Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
    Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
    Lipton RB; Pozo-Rosich P; Blumenfeld AM; Li Y; Severt L; Stokes JT; Creutz L; Gandhi P; Dodick D
    Neurology; 2023 Feb; 100(8):e764-e777. PubMed ID: 36396451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Schwedt TJ; Lipton RB; Ailani J; Silberstein SD; Tassorelli C; Guo H; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    Cephalalgia; 2022 Jan; 42(1):3-11. PubMed ID: 34521260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
    Croop R; Lipton RB; Kudrow D; Stock DA; Kamen L; Conway CM; Stock EG; Coric V; Goadsby PJ
    Lancet; 2021 Jan; 397(10268):51-60. PubMed ID: 33338437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
    Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M
    J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
    Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
    Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.